LM-108

LM-108 is a monoclonal antibody developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical and LaNova Medicines. The sponsor describes its target as CCR8, which OnCo does not yet have a target page for. ClinicalTrials.gov describes the intervention as: LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumour sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody. Oxaliplatin is a third-ge. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), in pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer. The largest, NCT07362186, plans to enrol 400 participants with primary completion expected 2028-08-17. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.